Connect with us


CBD hits the sweet spot



The London Botanists founder Chloe Lawrence-Green had a high-stress job in the city when she first discovered CBD – now she’s helping others find their bliss.

Chloe Lawrence-Green used to take CBD oil to lower her stress levels before a big meeting. These days it’s her own products that are helping busy professionals find moments of calm.

A former management consultant, Chloe’s life took a step-change when she set up premium CBD brand The London Botanists in 2018.

It may seem an unlikely move but like everything about the brand, it’s actually pretty simple; Chloe couldn’t find the products she wanted on the market, so she created them herself.

“I started taking CBD when I worked in the city to manage my stress levels. I would take a few drops before a big meeting as I found it calmed my mind allowing me to perform better,” she said.

“When I first tried CBD oil I noticed the difference straight away, but I struggled to find products I was happy with.

“I wanted natural, pure ingredients, ethically sourced, crafted with care and transparently labelled. Unfortunately after lots of research into the different brands on the market I realised this wasn’t always the case – so I decided to do it myself.”

The family-run London Botanists was born with a clear aim, to let nature do its thing.

The company keeps everything as natural as possible, from the ingredients they source to the packaging their products are sent out in, believing a business should tread ‘as lightly as possible’.

Only using farms with the highest standards in ethical, sustainable and organic farming techniques the team is constantly working with their partners to ensure they are pesticide and GMO-free.

READ MORE  MGC Pharma gets go-ahead for trial in Covid-19 patients

They then use the latest low-temperature CO2 method to extract the CBD, which is refined by removing waxes, fats and lipids to ensure the full-spectrum oil is free from unwanted compounds and has the maximum level of cannabinoids, flavonoids, phytonutrients, terpenes and natural minerals.

“As a family we have always felt very strongly about natural, organic products and holistic living, so CBD is something we’re really passionate about,” said Chloe.

“We only use the best raw materials from trusted suppliers, so we know exactly where and how everything was made.

She added: “We are targeting adults who are passionate about improving their wellness naturally, with premium and ethically sourced CBD.

“We use as few ingredients as possible, avoiding unnecessary additives and fillers and independently lab test our products so our customers know exactly what they’re getting.” 

The latest product to hit the spot is their CBD milk chocolate bar, a 43 percent, single-origin milk chocolate bar crafted from Venezuelan beans and infused with their best-selling oil.

The premium cacao and CBD contain Anandamide (AEA) –  a neurotransmitter produced in the body which is known as the ‘bliss molecule’ – as well as compounds that slow its breakdown, giving the body’s naturally-produced bliss a longer lifespan.

But the one to watch, Chloe claims is CBD skincare, with the company about to launch a CBD and rosehip skin balm to help soothe and relieve sensitive skin.

“The skincare trend has already begun but I believe it is only going to get bigger,” she said.

“More and more people are turning to CBD as they look for natural ways to manage their mental and physical health and improve all round wellness.

READ MORE  First study of cannabis in veterans with PTSD

“We expect this to only increase as peer-reviewed research sheds more and more light on the psychological and physiological benefits of CBD.”

The stats seem to agree, with The London Botanists online sales up by over a third since the coronavirus pandemic and a significant rise in online searches around CBD.

Now it’s keeping up with the demand for her products which has Chloe reaching for the bottle.

She added: “Nowadays my stresses have changed, but I still take CBD whenever I feel I need a little back up – for example on a Monday morning when racing to package up a weekend of orders and get them in the post.”







New studies examine effects of THC and CBD on stroke

New data suggests both positive and negative effects of cannabis in stroke patients



A new study has shown that pre-treatment CBD may have a neuroprotective effect in stroke patients.

The study aimed to investigate the effect of CBD on oxidative stress and cell death which occurs in ischemic stroke patients.

It revealed that the cannabinoid may reduce the destructive effects of cell damage associated with stroke.

Ischemic strokes are the most common type of stroke. They occur when a blood clot blocks a flow of oxygen or blood to the brain. This takes place in arteries that have been narrowed or blocked over time by fatty deposits (plaques). The most common symptoms of a stroke include facial drooping on one side, not being able to lift your arms and slurred speech.

If this occurs, it is vital that a person be taken to the emergency room immediately.

The National Institute of Health Care and Excellence (NICE) estimate that there are around 100,000 strokes every year in the UK. It is also thought that 1.3 million people live with the effects of a stroke.

Stroke recovery and CBD results

The Study showed that CBD reduced the amount of infarction in those samples which had been given the cannabinoid. Infarction refers to the death of tissue as a result of a lack of blood supply and is commonly due to a blood vessel being obstructed or narrowed.

There were also differences in malondialdehyde level (MDA) – a common marker of oxidative stress – between the brains of the CBD group and the vehicle group.

It also revealed that CBD may help to protect tissue by preventing further damage.

READ MORE  CBD may reduce side effects associated with anti-seizure medications.

THC and stroke risk

Another recent study examined the effect that tetrahydrocannabinol (THC) could have on strokes. It found that it may increase the risk of a certain type of stroke among cannabis consumers.

According to findings, cannabis consumers who experience a stroke known as an aneurysmal subarachnoid haemorrhage (aSAH), are twice as likely to develop further complications.

An aSAH occurs when a weakened blood vessel bursts on the surface of the brain leading to bleeding between the brain and tissue that covers it. It can result in neurological disabilities, long-term slurred speech or even death. It is estimated that aSAH affects around eight people per 100,000 of the population each year, accounting for six per cent of first strokes.

The study by the American Stroke Association suggested there is twice the risk of developing delayed cerebral ischemia for cannabis consumers. The researchers analysed data from 1,000 patients who had received treatment for bleeding over a 12 year period. In the group of participants, 36 per cent developed cerebral ischemia and 50 per cent had moderate to severe disabilities.

When comparing the results of patients who tested positive for THC with those who did not, they found cannabis consumers were 2.7 times more likely to develop cerebral ischemia. They were also 2.8 times more likely to develop long-term moderate to severe physical disabilities.

However, compared to those who tested negative for THC, the cannabis group did not have larger aneurysms, higher blood pressures or worse stroke symptoms when admitted to the hospital. They did not have any higher cardiovascular risk factors than the negative group.

READ MORE  Skin deep beauty: How can CBD help to save our skin?

Researchers are now conducting further studies in which they hope to better understand if THC can impact aneurysm formation and rupture.

Stroke: A banner advert for cannabis health news sign ups

Continue Reading


New study shows CBD may prevent Covid-19 infection

Researchers are calling for more trials to determine if CBD could be a preventative or early treatment for the virus.



Covid: A covid infection

Researchers are recommending clinical trials to examine if CBD could help to prevent Covid infection after more positive findings have been published.

Researchers from the University of Chicago have reported that CBD may stop the infection of Covid-19 by blocking its ability to replicate in the lungs.

A number of cannabinoids including CBD and THC were tested along with 7-Hydroxycannabidiol (7-OH-CBD) which is thought to be produced when cannabidiol is processed by the body.

The study found that CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of patients who were taking  high doses of CBD, prescribed for epilepsy.

As a result of their findings, researchers are calling for more clinical trials to determine whether CBD could eventually be used as a preventative or early treatment for the virus.

Covid- Covid infection

Covid and CBD study

Researchers treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to SARS-CoV-2 and monitoring them for the virus and the viral spike protein.

They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate.

Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.

CBD did not affect the ability of SARS-CoV-2 to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

Like all viruses, SARS-CoV-2 affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs.

READ MORE  CBD may reduce side effects associated with anti-seizure medications.

When it came to the other cannabinoids, CBD was found to be the only potentially potent agent. There was no or limited antiviral activity noted by the similar cannabinoids including THC, CBDA, CBDV, CBC or even CBG.

Marsha Rosner, PhD, professor and senior author of the study said it was a completely unexpected result, she commented: “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells.

She added: “We just wanted to know if CBD would affect the immune system. No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers do caution that this is not possible with commercially available CBD. The CBD tested was high-purity and also medical grade.

However, Rosner cautioned:  “Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything. The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation.”

CBD and Covid studies

This is the second study to be released showing the potential for cannabinoids in Covid management and prevention.

A study by Oregon State University has revealed that the compounds cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA), may have the ability to prevent the virus that causes Covid-19 from entering human cells.

READ MORE  First study of cannabis in veterans with PTSD

Researchers and scientists, led by Richard van Breedan, found that a pair of cannabinoid acids bind to the SARS-CoV-2 spike protein, blocking a step in the process the virus takes for infection.

Targeting compounds that block the virus-receptor interaction has been helpful for patients with other viral infections such as HIV-1 and hepatitis.

The researchers and scientists identified the two cannabinoid acids through a screening technique, developed previously in van Breeman’s laboratory. The team also screened different botanicals such as red clover, hops, wild yam and three types of liquorice.

Continue Reading


Partner of Irish politician “six years seizure free” faces charges over medical cannabis use

John Montaine uses medical cannabis to manage his epilepsy – and is said to be six years seizure free.



Irish government medical cannabis
John Montaine, is the partner of Clare Sinn Fein TD Violet Ann Wynne.

The partner of a sitting Irish TD is contesting charges of cannabis possession, saying he uses it medicinally to manage his epilepsy.

John Montaine, who is the partner of Clare Sinn Fein TD Violet Ann Wynne, was charged with the alleged illegal possession of cannabis on February 11, 2021, at his family home, the Irish Independent reported.

Mr Montaine contests the charges and his partner Deputy Wynne has previously spoken publicly about how he uses cannabis medicinally to manage his epilepsy.

Speaking after the initial court hearing in November, Deputy Wynne said in March her partner would be “six years seizure free”.

She went on to say that it has improved his quality of life “100 per cent, without a doubt”.

“There was always some kind of issue – say John having a number of fits within the one month or losing teeth or suffering with severe migraine, but since John has been using the medicinal cannabis, he has had a better quality of life,” Deputy Wynne told the Independent.

She added: “It has also freed myself up. John would have been on disability allowance and I would have had to have been his carer but since using the medicinal cannabis, he doesn’t suffer from any of those issues any longer.”

Medical cannabis is legal in Ireland, but access to a prescription is limited.

Last year Ryan Gorman, a 26-year-old man, from Dublin, who also suffers from epilepsy, became the first patient to receive a cannabis-based medicine through the Medical Cannabis Access Programme.

Despite legislation being signed off in 2019, Ireland’s Health minister Stephen Donnelly only announced funding for it in January 2021, with the programme only becoming fully operational in November.

Four cannabis-based medicines are expected to be available through the MCAP, to people living with one of three qualifying conditions. These include intractable nausea and vomiting associated with chemotherapy, severe treatment-resistant epilepsy and spasticity associated with multiple sclerosis (MS). 

Mr Montaine’s solicitor appeared in Kilrush District Court on behalf of his client this week, where his case was adjourned until 15 March.

READ MORE  New data on opioid-related A&E visits debunks cannabis "gateway drug" theory
Continue Reading